Important Dates

no event

Latest News

Enroll-HD periodic dataset – PDS7

The seventh release of the Enroll-HD periodic dataset, PDS7, has been fully curated and is now available. PDS7 contains data from 30,511 Enroll-HD study participants encompassing 112,992 study visits, making it one of the largest cohort datasets available to researchers. Read more here. […]

Read More…

next steps for Pridopidine

On 25 July, Prilenia shared that the application for pridopidine had been rejected for marketing authorisation in HD by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The application was based on post-hoc analyses from the EHDN-endorsed, Phase 3 PROOF-HD study, suggesting that the orally administered sigma-1 receptor agonist may offer potential […]

Read More…

Postcard from Palm Springs 2025

Published by CHDI, ‚Postcards From…‘ is a series of short videos aimed at non-scientists that conveys the major themes, scientific breakthroughs, and clinical trial updates from each year’s Huntington’s Disease Therapeutics Conference held (most usually) in Palm Springs, California. Beginning in 2006, this series of conferences is a unique forum where researchers from academia meet […]

Read More…

MDS-PAS and EHDN Joint Online Course Series: Multidisciplinary Management of Huntington’s Disease

Serie de Cursos Conjuntos en Línea MDS-PAS y EHDN: Manejo Multi- disciplinario de la Enfermedad de Huntington Course Format Start Date End Date Live Online Fri, Aug 15, 2025 Fri, Aug 22, 2025 Program Description Serie de Cursos Conjuntos en Línea MDS-PAS y EHDN: Manejo Multi- disciplinario de la Enfermedad de Huntington: Retos actuales y […]

Read More…

PIVOT-HD Achieves Primary Endpoint

On 5 May 2025, PTC Therapeutics shared a press release reporting results from the PIVOT-HD study of PTC518 (votoplam), a small molecule splicing modifier. This Phase 2, 12-month trial assessed the pharmacodynamic effect and safety of PTC518 at 5 mg and 10 mg compared to placebo in participants defined as HD-ISS Stage 2 or Stage […]

Read More…